Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.79 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.66 |
| ▸ | WNT3A | P56704 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | PIM1 | P11309 | 1/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.58 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | GABRP | O00591 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29988308 | 1.00 | GPR84 (0.79) | GPR84TP53SMN1; SMN2NPSR1CTNNB1 | |
| SCHEMBL2028344 | 0.88 | GPR84 (1.00) | GPR84TP53SMN1; SMN2NPSR1CTNNB1 | |
| SCHEMBL6247701 | 0.88 | GPR84 (0.71) | GPR84TP53SMN1; SMN2NPSR1CTNNB1 | |
| SCHEMBL12707173 | 0.88 | CFTR (0.61) | GPR84TP53SMN1; SMN2NPSR1CTNNB1 | |
| SCHEMBL22634965 | 0.87 | GPR84 (0.65) | GPR84TP53SMN1; SMN2NPSR1CTNNB1 | |
| SCHEMBL27694373 | 0.86 | GPR84 (0.69) | GPR84TP53SMN1; SMN2NPSR1CTNNB1 | |
| SCHEMBL9545117 | 0.86 | GPR84 (0.69) | GPR84TP53SMN1; SMN2NPSR1CTNNB1 | |
| SCHEMBL6705760 | 0.86 | GPR84 (0.69) | GPR84TP53SMN1; SMN2NPSR1CTNNB1 | |
| SCHEMBL2980233 | 0.86 | SMN1; SMN2 (0.71) | GPR84TP53SMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL64182 | 0.84 | GPR84 (0.77) | GPR84CTNNB1WNT3AALDH1A1PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6242449-B1 | TREATING PROSTATIC HYPERTROPHY, URINATION DISORDERS ASSOCIATED WITH PROSTATIC HYPERTROPHY, MALE PATTERN ALOPECIA, OR ACNE | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2001-06-05 | — | — | US | claimed |
| CN-1264365-A | 3-benzoylindole derivatives and drugs containing the same | ZERIA PHARM CO LTD (JP) | 2000-08-23 | — | — | CN | claimed |
| EP-0997457-A1 | 3-BENZOYLINDOLE DERIVATIVES AND DRUGS CONTAINING THE SAME | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2000-05-03 | — | — | EP | claimed |
| CN-1049156-A | Indenoindole compounds | UNIV BATH (GB) | 1991-02-13 | — | — | CN | claimed |
| WO-1990015800-A1 | INDENOINDOLE COMPOUNDS | UNIVERSITY OF BATH (GB) | 1990-12-27 | — | — | WO | claimed |
| EP-0404536-A1 | Indenoindole compounds I | UNIVERSITY OF BATH (GB) | 1990-12-27 | — | — | EP | claimed |
| JP-11035558-A | — | — | None | — | — | JP | disclosed |
| US-11891386-B2 | Indole compounds and their use | ARIAGEN, INC. (CA) | 2024-02-06 | — | — | US | disclosed |
| US-20230278986-A1 | ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230278986-A1 | ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230278986-A1 | ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230145074-A1 | Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230145074-A1 | Indole Compounds and Their Use | ARIAGEN, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-1999003831-A1 | 3-BENZOYLINDOLE DERIVATIVES AND DRUGS CONTAINING THE SAME | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-01-28 | — | — | WO | disclosed |
| EP-0734386-A1 | PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES | Abbott Laboratories (US) | 1996-10-02 | — | — | EP | disclosed |
| US-5486525-A | ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 1996-01-23 | — | — | US | disclosed |
| WO-1995016687-A1 | PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES | ABBOTT LABORATORIES (US) | 1995-06-22 | — | — | WO | disclosed |
| CN-1056685-A | Indole derivatives and preparation method thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1991-12-04 | — | — | CN | disclosed |
| US-4731353-A | METAL SALT OF INDOLE-2-CARBOXYLIC ACID COLOR DEVELOPER | KANZAKI PAPER MANUFACTURING COMPANY, LIMITED (JP) | 1988-03-15 | — | — | US | disclosed |
| US-4110536-A | ANTIARRHYTHMIA | MILES LABORATORIES, INC. (US) | 1978-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891386-B2 | Indole compounds and their use | IDO1, IDO2, INMT | GPR84 801/4885TP53 24/4885SMN1; SMN2 4567/4885 |
| US-20230278986-A1 | ARYL HYDROCARBON RECEPTOR MODULATORS AND USES THEREOF | AHR, ARNT, NR4A1 | GPR84 80/4885TP53 1611/4885SMN1; SMN2 4063/4885 |
| US-20230145074-A1 | Indole Compounds and Their Use | IDO1, IDO2, INMT | GPR84 801/4885TP53 24/4885SMN1; SMN2 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.